Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 6,471,860 | 3,836,629 | 6,000,577 | 4,929,228 | 4,805,735 | 26,044,029 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 6,471,860 | 3,836,629 | 6,000,577 | 4,929,228 | 4,805,735 | 26,044,029 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | 26,044,029 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 6,471,860 | 3,836,629 | 6,000,577 | 4,929,228 | 4,805,735 | 26,044,029 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 45,248 | 14,534 | 21,568 | 129,201 | 158,216 | 368,767 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 26,412,796 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 23017659 |
| Software Version: | 23.1.0.0 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part III, Line 4a | The Pediatric Brain Tumor Foundation released the Voice of the Patient report, highlighting the impact of pediatric lowgrade glioma pLGG and the experiences of patients, families, and caregivers. Based on input from an Externally led Patient-Focused Drug Development EL-PFDD meeting and additional feedback, the report underscores the urgent need for innovative pLGG treatments with fewer side effects that preserve cognitive and functional abilities. Submitted to the FDA, this report represents a significant step in advocating for improved treatment options for the pLGG community. The FDAs approval of OJEMDA tovorafenib, for pediatric low-grade glioma pLGG, the most common brain tumor in children, was a significant breakthrough in treatment options. In 2007, a group of Boston-area families, shocked by the toxicity and lack of effectiveness of treatment options for their children, created the PLGA Foundation/A Kids Brain Tumor Cure AKBTC, to fund research dedicated to understanding and treating pLGG. The PLGA Foundation/AKBTC, which later became the PLGA Fund at PBTF, supported research and clinical trials that led to this breakthrough. PBTF played a key role in advancing OJEMDA by funding research and amplifying the patient voice, continuing its commitment to improving treatments for children with brain tumors. We also want to thank to Catching Up With Jack and the Hope for Kidsfund for their generous support of the novel therapeutic target grant, and Jacks Drive 55 Foundations contributions to both grants through PBTFs PLGA Fund. The Pediatric Brain Tumor Foundations partnership with Uber, launched in November 2024, provided affordable, reliable transportation to help families affected by pediatric brain tumors access critical medical care. This pilots success only reinforces the necessity of sustaining and expanding such initiatives to meet growing demand. 181 unique families were supported and 51 hospital partners engaged. This past holiday season, Jazwares played a crucial role in bringing joy to children in hospitals receiving treatment for brain tumors. Starting on Giving Tuesday, donations transformed into PBTF gifting a comforting Squishmallows to a child undergoing treatment for a brain tumor, generously donated by Jazwares. This initiative raised critical awareness, further engaging donors by transforming each contribution into a meaningful gesture of hope and generosity. Together, we connected with more patient families, care teams, and communities across the country, creating a collective effort to offer comfort, hope, and joy while advancing groundbreaking research, making the holiday season truly special for the children and families who needed it most. The Pediatric Brain Tumor Foundation PBTF is strengthening its efforts with new leadership andexpanded services. Scott Kennedy joins as Vice President of Medical Stewardship and Research, bringing 20 years of experience to drive innovation and family-focused funding. PBTF has also added a nurse navigator and bilingual social worker, with plans to grow nationwide support for families. These advancements reinforce PBTFs commitment to research and comprehensive family care. As we continue to build momentum in research, care, and board development, were excited to launch the Next Gen Leadership Initiative, a network of rising professionals dedicated to advancing PBTFs mission through fundraising, networking, and advocacy. Focused on sustainability and growth, this diverse group spans industries like finance, technology, and healthcare, with many having a personal connection to the cause. Starting in the NYC Metro area, the initiative aims to expand nationwide, empowering emerging leaders to create a lasting impact. The Hearst Foundation has awarded the Pediatric Brain Tumor Foundation a 100K grant to fund the first year of a 3-year Early Career Development ECD research award. This program supports young scientists in pediatric brain tumor research by providing resources, mentorship, and funding. By fostering fresh perspectives and innovative ideas, the program aims to advance treatments and ensure a strong pipeline of experts dedicated to improving outcomes for children and their families. With this vital funding, we are proud to support the next generation of researchers working tirelessly to discover a cure for pediatric brain tumors. |
| Form 990, Part VI, Section A, Line 1A | The Board of Directors may, by resolution, designate two 2 or more Directors to constitute an Executive Committee, which the Committee, to the extent provided in such resolution, shall have and may exercise all of the authority of the Board of Directors in the management of the corporation except as otherwise required by law. All members of the Executive Committee shall be Directors of the corporation. Vacancies in the membership of the Committee shall be filled by the Board of Directors at any annual or special meeting of the Board of Directors. The Executive Committee shall keep regular minutes of its proceedings and report the same to the Board. |
| Form 990, Part VI, Section B, Line 11B | Upon receiving a final draft, the return was presented at a scheduled Board meeting. The return was presented to the full Board by the management of the organization, and a period of time for questions and comments was allowed. |
| Form 990, Part VI, Section B, Line 12C | All financial transactions both revenue and expenses are conducted with the knowledge and/or approval of either the President/CEO or the CFO. These transactions are reviewed for any potential conflicts of interest. Any interests are brought to the attention of the Executive Committee. |
| Form 990, Part VI, Section B, Line 15 | The Boards Executive Committee determines compensation and benefits for the President/CEO after reviewing the most current Guidestar nonprofit compensation report, other comparable data, scope of responsibility, size of organization, responsibility and budget to determine the reasonableness of the salary. |
| Form 990, Part VI, Section C, Line 18 | Recent filings of the Form 990 are available online at curethekids.org, Guidestar, and charity navigator. |
| Form 990, Part VI, Section C, Line 19 | The Foundation makes its governing documents, conflict of interests policy, and financial statements available via written request. Additionally, these documents are made available to all state governments that require annual filling of charitable organizations. |
| Form 990, Part XII, Line 2C | The process has not changed from the prior year. |
| Software ID: | 23017659 |
| Software Version: | 23.1.0.0 |